Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Funko Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.89 (market cap $8.04B), while Funko Inc trades at $5.66 (market cap $310.19M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 25.9× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | FNKO | |
|---|---|---|
Market Cap | $8.04B | $310.19M |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $5.88 |
52-Week Low | $241.71 | $2.46 |
Enterprise Value | $7.85B | $555.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FNKO trades at $5.69, up 1.97% with a bullish technical signal. Recent earnings beat expectations, yet the company reported a net loss of $67.36M in 2025. Revenue declined to $908.21M, but Q1 2026 showed improvement. Analyst consensus is mixed with 42.86% buy ratings. Cash flow trends are stabilizing, though negative profitability and high debt remain concerns.
Outlook hinges on execution of new product launches and cost management. Opportunities include brand strength and collectibles demand, but risks involve sustained losses, competitive pressure, and leverage. The stock presents a speculative growth play with significant turnaround requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
